Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-17 9:37 pm Purchase | 2025-12-31 | 13G | Revelation Biosciences, Inc. REVB | Armistice Capital, LLC | 288,332 4.990% | 225,643 (+359.94%) | Filing History |
| 2026-01-20 8:31 pm Purchase | 2025-12-31 | 13G | Revelation Biosciences, Inc. REVB | SABBY MANAGEMENT LLC | 151,426 9.600% | 151,426 (New Position) | Filing History |
| 2025-11-14 6:15 pm Purchase | 2025-09-30 | 13G | Revelation Biosciences, Inc. REVB | Armistice Capital, LLC | 62,689 9.990% | 62,689 (New Position) | Filing History |
| 2025-01-02 8:40 pm Purchase | 2024-12-31 | 13G | Revelation Biosciences, Inc. REVB | SABBY MANAGEMENT LLC | 2,172 4.900% | 2,102 (+3002.34%) | Filing History |
| 2024-02-13 8:12 pm Purchase | 2023-12-31 | 13G | Revelation Biosciences, Inc. REVB | Lind Global Fund II LP | 971 2.900% | 939 (+2900.00%) | Filing History |
| 2024-02-12 10:19 am Sale | 2023-12-31 | 13G | Revelation Biosciences, Inc. REVB | AXA IM Prime Impact Master Fund I SCA SICAV-RAIF | 292 0.900% | -49 (-14.29%) | Filing History |
| 2024-01-03 08:36 am Purchase | 2023-12-31 | 13G | Revelation Biosciences, Inc. REVB | SABBY MANAGEMENT LLC | 70 11.000% | 70 (New Position) | Filing History |
| 2023-02-21 4:49 pm Purchase | 2023-02-13 | 13G | Revelation Biosciences, Inc. REVB | Lind Global Fund II LP | 32 5.200% | 32 (New Position) | Filing History |
| 2023-02-21 06:02 am Purchase | 2023-02-09 | 13G | Revelation Biosciences, Inc. REVB | Mitchell P. Kopin | 32 4.990% | 32 (New Position) | Filing History |
| 2023-02-14 12:39 pm Purchase | 2022-12-31 | 13G | Revelation Biosciences, Inc. REVB | AXA IM Prime Impact Master Fund I SCA SICAV-RAIF | 340 8.320% | 340 (New Position) | Filing History |
| 2023-02-06 2:39 pm Unchanged | 2022-12-31 | 13G | Revelation Biosciences, Inc. REVB | Weiss Asset Management LP | 0 0.000% | 0 (Unchanged) | Filing History |
| 2023-01-31 3:31 pm Sale | 2022-12-31 | 13G | Revelation Biosciences, Inc. REVB | Linden Capital L.P. | 4 3.000% | -0 (-10.01%) | Filing History |
| 2022-08-17 4:56 pm Sale | 2022-02-28 | 13G | Revelation Biosciences, Inc. REVB | Meteora Capital, LLC | 0 0.000% | -4 (Position Closed) | Filing History |
| 2022-03-24 09:16 am Purchase | 2021-12-31 | 13G | Revelation Biosciences, Inc. REVB | Meteora Capital, LLC | 4 11.400% | 4 (New Position) | Filing History |
| 2022-03-10 4:03 pm Sale | 2022-02-28 | 13G | Petra Acquisition, Inc. PAIC | KARPUS MANAGEMENT, INC. | 0 0.000% | -841,120 (Position Closed) | Filing History |
| 2022-02-14 8:27 pm Purchase | 2022-02-04 | 13D | Revelation Biosciences, Inc. REVB | TIDMARSH GEORGE F | 10 14.100% | 10 (New Position) | Filing History |
| 2022-02-14 4:50 pm Sale | 2021-12-31 | 13G | Petra Acquisition, Inc. PAICU | Glazer Capital, LLC | 0 0.000% | -404,206 (Position Closed) | Filing History |
| 2022-02-14 4:25 pm Sale | 2021-12-31 | 13G | Petra Acquisition, Inc. PAIC | KARPUS MANAGEMENT, INC. | 841,120 12.830% | -36,253 (-4.13%) | Filing History |
| 2022-02-11 1:30 pm Unchanged | 2021-12-31 | 13G | Revelation Biosciences, Inc. REVB | Polar Asset Management Partners Inc. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2022-02-09 3:24 pm Purchase | 2021-12-31 | 13G | Revelation Biosciences, Inc. REVB | Weiss Asset Management LP | 2 5.370% | 2 (New Position) | Filing History |